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A B S T R A C T Protein kinase B (PKB/
) plays a key role in cell signaling. The PH domain of PKB binds phosphatidylinositol 3,4,5-trisphosphate translocating PKB to the plasma membrane for activation by 3-phosphoinositide-dependent protein kinase 1. The crystal structure of the headgroup inositol 1,3,4,5-tetrakisphosphate Ins(1,3,4,5)P 4 -PKB complex facilitates in silico ligand design. The novel achiral analogue benzene 1,2,3,4-tetrakisphosphate (Bz(1,2,3,4)P 4 ) possesses phosphate regiochemistry different from that of Ins(1,3,4,5)P 4 and surprisingly binds with similar affinity as the natural headgroup. Bz(1,2,3,4)P 4 co-crystallizes with the PKB␣ PH domain in a fashion also predictable in silico. The 2-phosphate of Bz(1,2,3,4)P 4 does not interact with any residue, and the D5-phosphate of Ins(1,3,4,5)P 4 is not mimicked by Bz(1,2,3,4)P 4 . Bz(1,2,3,4)P 4 is an example of a simple inositol phosphate surrogate crystallized in a protein, and this approach could be applied to design modulators of inositol polyphosphate binding proteins.
T he protein kinase B (PKB, also known as Akt) subfamily of protein kinases consists of three members (PKB␣/ Akt1, PKB␤/Akt2, and PKB␥/Akt3) with distinct cellular functions (1) (2) (3) . The activation mechanism of PKB has been extensively studied (4) and depends on the generation of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ) from phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P 2 ) on the plasma membrane by phosphoinositide 3-kinase (5) . The pleckstrin homology (PH) domain of PKB binds to PtdIns(3,4,5)P 3 , and this interaction recruits PKB to the plasma membrane (6) ; PKB is subsequently activated by phosphorylation at two sites (7) . The PH domain of PKB can also bind phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P 2 ) (8-10), and the headgroup derivatives myo-inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P 4 , 1a and 1b in Figure 1 ) and myo-inositol 1,3,4-trisphosphate (Ins(1,3,4)P 3 ). Importantly, the 5-phosphate of both PtdIns(3,4,5)P 3 and Ins(1,3,4,5)P 4 is solvent-exposed and not actively contributing to PKB PH domain binding (11) . Cellular levels of PtdIns(3, 4,5)P 3 are tightly controlled, and PKB activation is negatively regulated by the tumor suppressor phosphatase PTEN (protein phosphatase and tensin homologue deleted on chromosome 10), which dephosphorylates PtdIns(3,4,5)P 3 at the D3-position (12) . In cells lacking PTEN, PKB is constitutively active, which exerts its antiapoptotic effects and leads to tumor growth. Therefore, specific PKB inhibitors may deliver a targeted strategy to address patients who suffer from PTEN-induced tumors (13) .
Crystal structures of Ins(1,3,4,5)P 4 bound to the PH domains of a number of proteins have been reported; two of these are PKB (11) and 3-phosphoinositide-dependent protein kinase 1 (PDK-1) (14) . The design of ligands that interact with PH domains is attractive, potentially providing tools that decouple PtdIns binding from kinase activation. There is a recognized but unmet need to develop simple mimics of inositol polyphosphates (15) . Benzene polyphosphates are such molecules, in which the inositol ring is replaced by an aromatic core (16) , but their application has never been evaluated in a structural context. Only the phosphates can engage in any flexible movement for benzene polyphosphates; additionally, even this will be different compared to an inositol polyphosphate, and any conformational flexibility derived from the inositol ring will be blocked.
We discovered that benzene 1,2,3,4-tetrakisphosphate (Bz(1,2,3,4)P 4 , 2) binds to and co-crystallizes with the PH domain of PKB␣. Bz(1,2,3,4)P 4 is one of three regioisomeric benzene tetrakisphosphates and wassynthesized from 2,3,4-trihydroxybenzalde- hyde (3 in Figure 1 ). Triol 3 was benzylated to afford 2,3,4-tri-O-benzyloxybenzaldehyde 4, which was oxidized to the formate ester 5 and then hydrolyzed to give 2,3,4-tribenzyloxyphenol 6. The benzyl groups were removed to give 1,2,3,4-tetrahydroxybenzene 7 (17) , and the hydroxyl groups were phosphorylated using a modified method initially developed by Silverberg (18) to give compound 8 in 60% yield. The benzyl protecting groups of 8 were deblocked to give the crude product 2, which was purified over a column of Q-Sepharose Fast Flow using a gradient of triethylammonium bicarbonate buffer to give pure tetrakisphosphate 2 in 69% yield.
Importantly, using quantitative timeresolved FRET (TR-FRET) analysis of the glutathione S-transferase (GST)-tagged PH domain in complex with Eu-chelated anti-GST antibody, biotinylated PtdIns(3,4)P 2 , and streptavidin-coated allophycocyanin (APC) (14) , it was found that the pIC 50 for Bz(1,2,3,4)P 4 binding to PKB␣ is 6.35 Ϯ 0.15 (mean Ϯ standard error of the mean (SEM), n ϭ 4), giving a K i of 0.08 M (Supplementary Figure 1) . For comparison, the natural headgroup Ins(1,3,4,5)P 4 has a pIC 50 of 6.22 Ϯ 0.2 (mean Ϯ SEM, n ϭ 5) and K i value of 0.12 M. The pIC 50 for diC 8 PtdIns(3,4,5)P 3 is 5.92 Ϯ 0.09 (mean Ϯ SEM, n ϭ 3), and K i is 0.23 M. Since Bz(1,2,3,4)P 4 has good affinity for the PH domain of PKB, it effectively acts as an inositol polyphosphate surrogate.
Crystals of the PKB␣ PH domainBz(1,2,3,4)P 4 complex were grown after mixing purified PKB␣ PH domain (11) with 10-fold molar excess of Bz(1,2,3,4)P 4 . Highresolution (1.94 Å) diffraction data were collected, and the structure was solved by molecular replacement using the PKB␣ PH domain-Ins(1,3,4,5)P 4 complex (11) Table 2 ). The 1/D1-phosphate is closely enveloped by the Variable Loop-1 region (VL1, residues [16] [17] [18] [19] [20] , forming similar but not equivalent hydrogen bonds to backbone amide groups of the protein (Supplementary Table 2 ).
The "fit atoms" alignment tool was used within Sybyl 7.0 to determine the maximum possible overlap of Bz(1,2,3,4)P 4 and Ins(1,3,4,5)P 4 . The ligands were extracted from the experimental structures, and the equivalent heavy PKB inhibitors are a priority target of the pharmaceutical industry. Most inhibitors target the ATP binding site of the kinase domain and often prove to be non-specific (19, 20) . Therefore, small molecules that specifically target the PH domain of PKB should block its membrane localization and hence the conformational change prior to PKB activation (13) . The charges of benzene polyphosphates could be masked with acetoxymethyl or pivaloyloxymethyl groups to provide cell-permeable derivatives, enhancing their value as potential modulatory tools for cell biology.
The addition of Ins(1,3,4,5)P 4 to fulllength PKB in an in vitro kinase assay is insufficient to induce PKB activation (21) , and whether PKB binds to soluble inositol phosphates in vivo is debated (22) . Bz(1,2,3,4)P 4 has good affinity for the PKB␣ PH domain, as determined by TR-FRET. Recent data (22) show that Ins(1,3,4,5)P 4 could not compete with PtdIns(3,4,5)P 3 binding at the PH domain of PKB␣, whereas other data show an affinity of 168 M (23). Affinities of 1.5 M and higher have also been reported (9, 24) . There is no explanation for these differences at present; however, inositol phosphates clearly play an important role in regulating proteins with PH domains, for example, phospholipase C (PLC) ␦1(25) and PDK-1 localization in vivo (14) .
We describe the crystal structure of the novel PtdIns(3,4,5)P 3 headgroup mimic Bz(1,2,3,4)P 4 in complex with the PH domain of PKB␣ (Figure 2 ; Supplementary Table 1 ). Our modeling approaches indicate that the PKB-PH domain provides a robust scaffold for in silico ligand design. This is crucial, since more lipid-like derivatives that might directly interfere with PKB activation (similar to PtdIns(3,4,5)P 3 ether analogues) may be unsuitable for co-crystallization studies. We also demonstrate that for Bz(1,2,3,4)P 4 only the three phosphate groups equivalent to the 1,3,4-trisphosphate are required for binding, correlating with other crystallographic observations. There are many proteins that bind inositol phosphates and phospholipids. Enzymeresistant benzene polyphosphates could be used to replace inositol polyphosphates in other crystallization experiments where inositol polyphosphates may be modified by proteins such as phosphatases or kinases. Such inositol phosphate surrogates could be structurally tailored for each protein and should provide new tools to inhibit various inositol polyphosphate binding proteins and phosphoinositide modifying enzymes, as we have recently reported (26, 27) .
METHODS
Chemistry. Experimental details are similar to those described previously (26) . Bz(1,2,3,4)P 4 . The PKB␣ PH domain protein was expressed and purified as described previously (11) . The triethylammonium salt of Bz(1,2, 3,4)P 4 was solubilized directly in an 8.5 mg/mL PKB␣ PH domain solution to achieve a 10-fold molar excess of ligand over protein and incubated on ice for 1 h. Crystals of the protein-ligand complex were grown using the hanging drop vapor diffusion method derived from several conditions similar to those reported for the PKB␣ PH domain- Crystals were grown overnight at 20°C and reached their maximum size after 5 d. Prior to freezing, the crystals were soaked in crystallization solution enriched with 10% 2-methyl-2,4-pentanediol. Diffraction data to a resolution of 1.94 Å were collected at the European Synchrotron Radiation Facility in Grenoble, station ID14, at 100 K, and the structure was solved by rigid body refinement using CNS (28) . Subsequently, refinement was carried out in CNS, including extensive simulated annealing to reduce phase bias. Ligand topologies were generated using PRODRG (29) . See Supplementary Table 1 for data collection and refinement statistics.
Crystallography of PKB␣ PH Domain in Complex with
FRET Binding Experiments. The GST-tagged PH domain of PKB␣ was prepared as described in Supplementary Methods. The quantitative TR-FRET analysis of binding was performed in white 96-well plates (Greiner) using a BMG Labtech PHERAstar with the following settings: excitation 337 nm filter, emission 665 and 620 nm filters, 300 flashes per well, 10 s flashes, read for 400 s following a 50 s delay. Assays were performed in a buffer made of HEPES, 50 mM, pH 6.8; NaCl, 150 mM; MgCl 2 , 5 mM; DTT, 5 mM; CHAPS, 0.5%; EDTA, 1 mM in a final assay volume of 50 L.
The K d values for biotinylated diC 8 -PtdIns(3, 4)P 2 were determined by increasing amounts (0 -100 nM) of biotinylated diC 8 Figure 1) . IC 50 values were determined, and K i values were calculated (30) . All curve fitting and statistical analysis was performed using Prism (GraphPad).
Synthesis of 2,3,4-Tribenzyloxybenzaldehyde (4). 2,3,4-Trihydroxybenzaldehyde 3 (3.08 g, 20 mmol), cesium carbonate (32.58 g, 100 mmol), and benzyl bromide (11.9 mL, 100 mmol) in dry DMF (100 mL) were stirred for 21 h at 80°C. The yellow-brown solution was filtered over a bed of Celite and washed with acetone (200 mL). The solvents were evaporated, giving a red-brown oil that was partitioned between CH 2 Cl 2 and water (200 mL of each). The organic layer was dried, and the solvent was evaporated to give the crude compound. Compound 4 was purified by flash chromatography (CH 2 Cl 2 ) to give a white solid, R f ϭ 0.40 (CH 2 Cl 2 ), 7.73 g (91%), mp 74 -75°C (hexane).
Synthesis of 2,3,4-Tribenzyloxyphenol (6). 3-Chloroperoxybenzoic acid (2.9 g, 16.8 mmol) was added to a solution of 2,3,4-tri-O-benzyloxybenzaldehyde 4 (4.245 g, 10 mmol) in dry CH 2 Cl 2 (100 mL), and the mixture was stirred for 20 h at RT. The organic layer was washed with an aqueous solution of 10% sodium metabisulfite, a saturated solution of sodium hydrogen carbonate (2 ϫ 100 mL of each), and water (100 mL). The organic layer was dried, and the solvent was evaporated to give the crude formate ester 5 as a yellow syrup, R f ϭ 0.56 (CH 2 Cl 2 ). Compound 5 was dissolved in methanol (50 mL) containing 0.5 mL of concentrated HCl and 2.5 mL of water and then stirred for 2 h at RT. The reaction was neutralized using solid NaHCO 3 (5 g), the remaining solid was filtered, and the solvent was evaporated. Compound 6 was purified by flash chromatography (CHCl 3 ) and isolated as a pale yellow oil, R f ϭ 0.40 (CHCl 3 ), 3.485 g (84%).
Synthesis of 1,2,3,4-Tetrahydroxybenzene (7). 2,3,4-Tribenzyloxyphenol 6 (3.36 g, 8.15 mmol) was dissolved in ethanol (100 mL) followed by the addition of 20% palladium hydroxide (500 mg). The air was expelled from the vessel, and the mixture was stirred over an atmosphere of hydrogen for 24 h at RT. The solution was filtered over a bed of Celite, and the solvent was evaporated giving a beige solid, R f ϭ 0.40 (CH 2 Cl 2 /MeOH 9:1), 993 mg (86%); mp 162°C (ether/hexane). Synthesis of Benzene 1,2,3,4-tetrakisphosphate (2). Compound 8 (119 mg, 100 mol) and bromotrimethylsilane (1.0 mL, 7.58 mmol) were stirred in dry CH 2 Cl 2 (5 mL) for 2 d under an atmosphere of nitrogen. The solvents were evaporated to give a syrup that was dissolved in methanol (5 mL) and then stirred for 5 min. Compound 2 was purified by ion exchange chromatography over Q-Sepharose Fast Flow using a gradient of TEAB (0 ¡ 2.0 M) and eluted between 1.1 and 1.8 M buffer to give a glassy triethylammonium salt, 69 mg (69 mol, 69%).
PyMOL was used to generate all figures.
Accession Codes: The coordinates of the PKB␣ PH domain-Bz(1,2,3,4)P 4 complex have been submitted to the Protein Data Bank and are listed as 2UVM.
